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Characterizing hepatitis C virus 
epidemiology in Egypt: systematic 
reviews, meta-analyses, and meta-
regressions
Silva P. Kouyoumjian1, Hiam Chemaitelly  1 & Laith J. Abu-Raddad1,2
Egypt is the most affected nation by hepatitis C virus (HCV) and needs a comprehensive characterization 
of HCV epidemiology to inform the scale-up of treatment and prevention programs. Systematic 
reviews, meta-analyses, and meta-regressions were conducted. A total of 25 incidence, 259 
prevalence, and 47 genotype studies were identified. Incidence and prevalence levels were high 
across all populations. Genotype 4 accounted for 94.1% of infections with a relative Shannon Diversity 
Index of only 14.4%. Pooled mean HCV prevalence was estimated at 11.9% (95% CI = 11.1–12.6%) 
among the general population, 55.6% (95% CI = 49.4–61.7%) among populations at high risk, 
14.3% (95% CI = 10.3–18.8%) among populations at intermediate risk, 56.0% (95% CI = 50.4–61.6%) 
among populations with liver-related conditions, and 35.0% (95% CI = 27.3–43.1%) among special 
clinical populations. Mean HCV viremic rate was estimated at 66.7% (95% CI = 61.7–71.5%). Meta-
regression indicated 6% lower odds for HCV prevalence for each one-year increment in publication 
year (AOR = 0.94; 95% CI = 0.92–0.96). HCV prevalence is high with evidence for ongoing transmission 
mainly through healthcare. Genotype diversity is low with genotype 4 dominance. Two-thirds of 
antibody-positive Egyptians are chronically infected and need treatment. Clinical populations should be 
prioritized for screening. Despite the large-scale epidemic, prevalence appears to be declining rapidly 
consistent with a contracting epidemic.
Viral hepatitis was estimated to be the 7th leading cause of mortality globally1. About half of this mortality is 
attributed to hepatitis C virus (HCV), a primary cause for liver fibrosis, cirrhosis and cancer2,3. The recent devel-
opment of highly efficacious oral direct-acting antivirals (DAAs) provides opportunities for reducing HCV dis-
ease burden and its onward transmission, with the potential for eliminating this blood-borne virus as a public 
health concern4–7. The World Health Organization (WHO) has recently formulated the ‘Global Health Sector 
Strategy on Viral Hepatitis, 2016–2021’8 with service coverage targets to eliminate HCV as a public health threat 
by 20308,9. Action to combat viral hepatitis has now been integrated into the United Nations’ 2030 Agenda for 
Sustainable Development10.
One of the countries most affected by HCV is Egypt. The Egypt Demographic and Health Surveys (EDHS) 
measured antibody prevalence among the adult population aged 15–59 years at 14.7%11 in 2009 and at 10.0%12 in 
2015—substantially higher than global levels2,3,13. To attend to this challenge, Egypt developed a national strategy 
for HCV control and established HCV prevention and treatment programs14–16. Following successful negotiations 
for 99% discounted DAA prices17, Egypt launched an ambitious national HCV treatment program aiming to treat 
over 250,000 chronically infected individuals per year, with the goal of achieving a national chronic infection 
prevalence of <2% by 20255,18. Despite this progress, existing evidence suggests ongoing HCV transmission in 
Egypt, with higher incidence levels relative to other countries5,19–21.
The overarching goal of the present study was to provide a rigorous understanding of HCV epidemiology in 
Egypt with the ultimate aim of informing the rapidly expanding treatment and prevention national response. 
We aimed specifically to 1) characterize HCV infection levels across populations and subpopulations at various 
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risks of exposure, 2) assess the diversity in HCV genotype and subtype distributions, 3) estimate the mean 
anti-HCV prevalence among populations and subpopulations, 4) estimate the mean HCV viremic rate, 5) iden-
tify individual-level risk factors for incident HCV infection and factors associated with being infected with HCV, 
and 6) identify population-level associations with anti-HCV prevalence in the general population adjusting for 
different sources of between-study heterogeneity.
This study is conducted under the umbrella of the ongoing Middle East and North Africa (MENA) HCV 
Epidemiology Synthesis Project21–30. The project aims to promote an improved understanding of HCV epidemi-
ology and to provide the evidence necessary to guide research, policy, and programmatic efforts in this region.
Methods
We characterized HCV epidemiology in Egypt through several descriptive, analytical, and quantitative assess-
ments. We first conducted systematic literature reviews to expand and update our previously published review 
of HCV antibody incidence and prevalence in Egypt21 and to describe the diversity in HCV genotype and sub-
type distributions. We subsequently performed random-effects meta-analyses to estimate the mean anti-HCV 
prevalence among populations and subpopulations at various risks of exposure to the infection, and the mean 
HCV viremic rate—that is the mean proportion of individuals chronically infected with HCV (HCV RNA pos-
itive) among those antibody positive for HCV. We subsequently constructed and conducted random-effects 
meta-regression models to identify associations with anti-HCV prevalence among the general population and 
sources of between-study heterogeneity.
Systematic review of incidence of HCV infection and anti-HCV prevalence studies. We con-
ducted a systematic review of HCV antibody incidence (Table 1) and prevalence (Supplementary Tables S2–S4) 
among the Egyptian resident and expatriate populations following the Cochrane Collaboration guidelines31 
and reported the findings following the PRISMA guidelines32 (Fig. 1). The PRISMA checklist is provided in 
Supplementary Figure S1. We conducted an exhaustive search surveying international and regional databases as 
well as the grey literature using broad criteria with no language restrictions (Supplementary Figure S2).
After duplicates’ exclusion, screening of titles and abstracts was performed. Full-text screening of relevant or 
potentially relevant reports was further conducted. Hand searching of references of literature reviews was also 
implemented. Any report including primary data for HCV antibody incidence and/or prevalence qualified for 
inclusion in the review. Case reports, case series, editorials, letters to editors, commentaries, and studies reporting 
non-A non-B hepatitis were disregarded. Here, a “report” may include one or more outcomes of interest, while a 
“study” pertains to a specific outcome measure.
Data characterizing the identified HCV measures were extracted by SPK (Supplementary Table S1). 
Consistency checks for 10% of the extracted reports were performed by HC. Incidence of HCV infection studies, 
and anti-HCV prevalence studies with at least 50 participants, were synthesized by populations’ risk of exposure 
to the infection21,23–30 as follows:
 1. General populations: these include populations at relatively low risk of exposure to HCV such as blood 
donors, healthy children, antenatal clinic (ANC) attendees, pregnant women, and participants in house-
hold-based surveys, among others.
 2. Populations at high risk: these include people who inject drugs (PWID), and populations exposed to 
frequent medical injections and/or blood transfusions such as hemodialysis, thalassemia, hemophilia, and 
multi-transfused patients, among others.
 3. Populations at intermediate risk: these include populations whose risk of exposure is perceived to be 
higher than the general population, but lower than populations at high risk, such as healthcare workers, 
household contacts of HCV infected patients, patients with diabetes, and prisoners, among others.
 4. Populations with liver-related conditions: these include patients with liver-related conditions of an epide-
miological significance to HCV infection such as patients with chronic liver disease, acute viral hepatitis, 
hepatocellular carcinoma, and liver cirrhosis, among others. This category includes also non-Hodgkin’s 
lymphoma patients because of potential link to HCV infection33,34.
 5. Special clinical populations: these include patients whose risk of exposure to HCV is uncertain such as pa-
tients with non-liver related malignancies, dermatological manifestations, and rheumatological disorders, 
among others.
 6. Mixed populations: these include samples with a mix of the previously described populations. These were 
reported, but were excluded from further analyses.
Quality assessment for the identified measures was conducted as informed by the Cochrane Collaboration 
guidelines35 (Supplementary Figure S3 and Supplementary Tables S5–S9).
Systematic review of HCV genotypes. A second independent systematic review for HCV genotypes and 
subtypes among Egyptians was conducted following the same methodology (Fig. 2) and using the original broad 
search criteria (Supplementary Figure S2). Genotype, and where available, subtype information were extracted 
from all relevant studies irrespective of sample size (Supplementary Table S1). Frequency distributions were 
described (Fig. 3). Genotype diversity was quantified using Shannon Diversity Index36. The frequency distribu-
tion of genotypes was calculated with individuals testing positive for multiple genotypes contributing separately 
to each genotype in the distribution37 (Table 2).
Meta-analyses of anti-HCV prevalence measures among populations and subpopulations. 
Meta-analyses were performed to estimate the pooled mean anti-HCV prevalence among populations and 
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First author, year of 
publication [citation]
Year(s) 
of data 
collection Study site Population
Sample 
size at 
recruitment
Lost to 
follow-
up
HCV sero-
conversion 
risk (relative 
to total sample 
size)
HCV incidence 
rate (per 1,000 
person-years)
Total 
person-
years
Follow-up 
duration 
(months)
General population (n = 5)
Mohamed, 200548 1997–2000 Community
Household members 
surveyed in Aghour el 
Soughra village in Nile 
Delta
2,463 931 — 6.8 4,195 19
Mohamed, 200548 1997–2000 Community
Household members 
surveyed in Sallam village 
in Upper Egypt
4,275 2,443 — 0.8 6,720 19
Mostafa, 2010 49 2001–2006 Community
Household members 
surveyed in 3 villages in 
Menoufia governorate in 
Nile Delta
3,580 396 0.79 2.4 10,578 48
Mikhail, 200751 2000–2004 Community Control subjects surveyed in a village in Nile Delta 149 — — 10.2 — 10
Saleh, 200850 1997–2006 ANC
Pregnant women surveyed 
in 3 villages in Menoufia 
governorate in Nile Delta
2,171 — — 5.2 4,814 26
Populations at high risk (n = 7)
El-Sherif, 2012166 — Hospital Hemodialysis patients 14 — 21.4 — — 4
Goher, 199896 — Hemodialysis units Hemodialysis patients on non-reused dialyzers 37 — 21.6 — — 6
Goher, 199896 — Hemodialysis units Hemodialysis patients on reused dialyzers 53 — 20.8 — — 6
Khodir, 2012167 2011 Hemodialysis units Hemodialysis patients 1,527 — 11 — — 8
Soliman, 201392 2008–2010 Hospital and hemodialysis units
Hemodialysis patients 
following strict isolation 
program
27 — 14.8 — — 36
Soliman, 201392 2008–2010 Hospital and hemodialysis units
Hemodialysis patients not 
following strict isolation 
program
56 — 42.9 — — 36
Zahran, 201489 Hemodialysis units Hemodialysis patients 303 14.5 — — 36.7
Populations at intermediate risk (n = 4)
Abdelwahab, 201353 2008–2011 Hospital Healthcare workers 717 66 0.3 2.0 — 18
Munier, 201352 2008–2010 Hospital Healthcare workers 73 — 0 — — 6
Okasha, 201554 2008 Hospital Healthcare workers 402 102 1 7.3 551 18
Saleh, 201055 2000–2006 ANC Children of HCV infected mothers* 2,852 353 0.53 2.7 5,573 66
Populations with liver-related conditions (n = 2)
Meky, 2006168 2002–2005 Community
Small sub-sample of 
patients with liver 
disease biomarkers in a 
community study
6 — 33.3 — — 6
Mikhail, 200751 2000–2004 National liver endoscopy unit
Chronic liver disease 
patients undergoing 
endoscopy
149 — 2.7 — — 10
Special clinical populations (n = 1)
Hassan, 201356 — Hospital Stem cell transplant patients 50 — 4.0 — — —
Mother-to-child transmission (n = 6)
Abdul-Qawi, 201057 2003–2008 Hospital Infants of HCV Ab+and RNA+mothers 53 — 3.8 — — 6
Abo Elmagd, 201161 — — Infants of HCV Ab+and/or RNA+mothers 8
‡ — 25 — — 0-12ǁ
El-Sayed Zaki, 201362 2012–2013 Hospital Infants of HCV Ab+mothers 12 — 8.3 — — —
Kassem, 200059 1996 Hospital Infants of HCV Ab+and RNA+mothers 14 — 36 — — 0
†
Kumar, 19958 1994–1996 Hospital Infants of HCV Ab+and RNA+mothers 65 — 24.6 — — 18
Shebl, 200960 1998–2001 ANC Infants of HCV Ab+and/or RNA+mothers 232
** — 3.4 — — 24
Table 1. Studies reporting hepatitis C virus (HCV) antibody incidence in Egypt. *HCV infection among these 
children was community-acquired; **7 out of 232 infants were born to mothers who were only HCV RNA 
positive; †Blood samples collected at birth; ‡3 out of 8 infants were born to mothers who were only HCV RNA 
positive; ∥Infants’ ages ranged from 0 to 12 months. **Abbreviations: ANC, antenatal clinic; Ab, antibody; +, 
positive.
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subpopulations at various risks of exposure to HCV. Studies including at least 25 individuals qualified for inclu-
sion in meta-analysis. We substituted anti-HCV prevalence for the total sample with stratified measures whenever 
the required sample size was met at the stratum level. Only one stratification for each study was included in the 
meta-analysis following a pre-defined sequential order prioritizing: population, sex, year, region, and finally age.
For each meta-analysis, the variances of anti-HCV prevalence measures were first stabilized by imple-
menting Freeman-Tukey type arcsine square-root transformation38. The inverse variance was then used to 
weight anti-HCV prevalence measures which were then pooled into one summary estimate (for mean) using a 
DerSimonian-Laird random-effects model39. Heterogeneity was further assessed39,40 (Table 3).
Meta-analysis of HCV viremic rates. HCV RNA prevalence measures, identified through the HCV anti-
body incidence and prevalence systematic review, were synthesized by population’s risk of exposure to HCV 
(Supplementary Tables S1–S3). An estimate for the mean HCV viremic rate was subsequently generated by pool-
ing measures of HCV RNA positivity among anti-HCV positive persons using a random-effects meta-analysis, 
following the same protocol applied for the anti-HCV prevalence meta-analyses (Fig. 4).
Meta-analyses were conducted in R version 3.2.241 using the package meta42.
Meta-regression analyses. Meta-regression analyses were performed to identify associations with 
anti-HCV prevalence among the general population and sources of between-study heterogeneity (Table 4). 
Potential predictors were specified a priori and included: subpopulation type (blood donors; pregnant women/
ANC attendees; children; Egyptian expatriate workers mandatory pre-employment screening; other general 
Figure 1. Flow chart of article selection for the systematic review of hepatitis C virus (HCV) antibody 
incidence and prevalence in Egypt, adapted from the PRISMA 2009 guidelines32.
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population groups), region (Upper Egypt; Middle Egypt; Lower Egypt; Canal and Sinai; national; mixed regions; 
regions outside Egypt; unspecified), study site (blood bank; national; clinical; others; unspecified), sampling 
methodology (probability-based; non-probability based), sample size (<100; >=100), publication year, and 
median year of data collection. Associations were described using odds ratios (ORs), 95% confidence intervals 
(CIs) and p-values. Factors with a p-value < 0.1 in univariable analyses were eligible for inclusion in the initial 
multivariable model. Factors with a p-value < 0.05 were retained in the final model.
Meta-regressions were conducted in STATA version 1243 using the package metareg44.
Results
Systematic review of HCV antibody incidence and prevalence: study selection pro-
cess. Figure 1 shows the selection process for HCV antibody incidence and prevalence studies following 
PRISMA guidelines32. A total of 5,343 citations were identified (868 using PubMed, 1,347 using Embase, 3,121 
using other international and regional databases, and 7 using the MENA HIV/AIDS Epidemiology Synthesis 
Project database45,46). Out of these, 411 reports were considered relevant or potentially relevant after duplicates’ 
removal and titles and abstracts’ screening. A final of 233 reports qualified for inclusion in the systematic review 
after full-texts’ screening. The rest were excluded for different reasons outlined in Fig. 1. Two EDHS reports11,12, 
and an additional report47 identified through hand-searching other reviews’ bibliography, were also included.
To sum, the systematic review included 236 eligible reports reporting a total of 25 incidence of HCV infec-
tion studies and 259 anti-HCV prevalence studies. We report the decimal places of the prevalence and incidence 
Figure 2. Flow chart of article selection for the systematic review of hepatitis C virus (HCV) genotypes in 
Egypt, adapted from the PRISMA 2009 guidelines32.
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figures as in the original report, but we rounded the prevalence and incidence figures with more than one decimal 
places to one decimal place.
Overview of incidence of HCV infection. All of the 25 incidence of HCV infection studies were based 
on a prospective cohort design (Table 1). Only a third reported HCV incidence rate, while the rest reported sero-
conversion risk for anti-HCV.
Five studies were conducted among the general population. These reported incidence rates ranging between 
0.8 per 1,000 person-years among residents of a village in Upper Egypt, and 10.2 per 1,000 person-years among 
residents of a village in the Nile Delta48–51. The seven studies among populations at high risk, all among hemodi-
alysis patients, reported seroconversion risks for anti-HCV ranging between 11% and 42.9%. Four studies were 
conducted among populations at intermediate risk, three of which were among healthcare workers52–54 and one 
Figure 3. Distribution of hepatitis C virus (HCV) genotypes and subtypes among HCV RNA positive 
individuals in Egypt. (A) Distribution of HCV genotypes among HCV RNA positive individuals. (B) 
Distribution of HCV genotype 4 subtypes as available.
n %
Genotype 1 191 4.0
Genotype 2 60 1.2
Genotype 3 39 0.8
Genotype 4 4,735 94.1
Genotype 5 6 0.1
Genotype 6 — —
Genotype 7 — —
Shannon Diversity Index 0.27
Index relative to total possible diversity* 14.4%
Table 2. Frequency, distribution, and Shannon Diversity Index of identified hepatitis C virus (HCV) genotypes 
across Egypt. *The maximum value for Shannon Diversity Index is 1.95 assuming full genotype diversity of 
seven HCV genotypes30,37.
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was among children of HCV infected mothers55. Among healthcare workers, the first study reported no inci-
dence of HCV infection52, while the other two reported rates of 2.053 and 7.354 per 1,000 person-years. The study 
among children who were HCV negative at birth but had HCV infected mothers reported a rate of 2.7 per 1,000 
person-years55. A single incidence study was conducted among a special clinical population and reported a sero-
conversion risk for anti-HCV of 4% among stem cell transplant patients56.
Six incidence studies documented mother-to-child transmission. Out of these, three were conducted among 
infants born to anti-HCV positive and RNA positive mothers and reported a seroconversion risk for anti-HCV of 
3.8%57, 24.6%58, and 36%59. Two other studies among infants born to anti-HCV positive and/or HCV RNA posi-
tive mothers reported a seroconversion risk for anti-HCV of 3.4%60 and 25%61. One study among infants born to 
anti-HCV positive mothers assessed the seroconversion risk for anti-HCV at 8.3%62.
Studies Samples Prevalence Effect size Heterogeneity measures
Total N Total N Range (%) Mean (%) (95% CI) Q (p-value)* τ2**
I² (confidence 
limits)ǂ
Prediction 
interval (%)ǁ
All populations
General population 264 1,677,404 0.0–57.6 11.9 (11.1–12.6) 38,386.8 (p < 0.0001) 0.0257 99.3% (99.3–99.3%) 3.5–24.0
Populations at high risk 57 7,459 8.8–100 55.6 (49.4–61.7) 1,437.3 (p < 0.0001) 0.2079 96.1% (95.5–96.6%) 13.1–93.6
Populations at intermediate risk 45 9,427 0.0–90.0 14.3 (10.3–18.8) 1,436.2 (p < 0.0001) 0.1553 96.9% (96.4–97.4%) 0–51.0
Populations with liver-related 
conditions 72 47,214 4.3–100 56.0 (50.4–61.6) 7,777.2 (p < 0.0001) 0.2199 99.1% (99.0–99.2%) 12.8–94.2
Special clinical populations 34 5,542 0.5–96.1 35.0 (27.3–43.1) 1206 (p < 0.0001) 0.2256 97.3% (96.8–97.7%) 1.5–81.8
General population (populations at low risk)
Blood donors 116 1,566,669 0.0–38.0 10.4 (9.6–11.2) 24,513.7 (p < 0.0001) 0.0180 99.5% (99.5–99.6%) 3.6–20.0
  Family replacement 15 262,535 3.8–14.6 7.1 (5.9–8.3) 1,931.7 (p < 0.0001) 0.0080 99.3% (99.1–99.4%) 2.8–13.1
  Voluntary 27 1,025,535 0.7–27.2 5.4 (4.4–6.5) 9,700.4 (p < 0.0001) 0.0133 99.7% (99.7–99.8%) 1.3–12.2
Pregnant women 14 12,700 2.3–19.0 9.0 (6.0–12.6) 455.0 (p < 0.0001) 0.0405 97.1% (96.2–97.8%) 0.4–26.1
Children 10 3,408 0.0–38.0 6.4 (2.9–11.1) 171.6 (p < 0.0001) 0.0604 94.8% (92.2–96.5%) 0–28.2
Egyptian expatriate workers 
undergoing mandatory pre-
employment screening and Egyptians 
living abroad
23 9,168 0.0–38.4 14.4 (9.3–20.4) 1137.0 (p < 0.0001) 0.0349 98.1% (97.7–98.4%) 0–50.4
Other general populations 101 85,459 0.0–57.6 14.3 (12.3–16.4) 6472.6 (P < 0.0001) 0.0192 98.5% (98.3–98.6%) 0.9–38.3
Populations at high risk
Hemodialysis patients 26 4,915 10.0–100.0 65.5 (56.5–74.1) 809.1 (p < 0.0001) 0.2119 96.9% (96.2–97.5%) 18.9–98.6
Thalassemia patients 21 1,812 8.8–82.0 46.3 (34.9–57.9) 484.0 (p < 0.0001) 0.2710 95.9% (94.7–96.8%) 2.9–93.9
Multi-transfused patients 6 449 15.2–81.6 42.9 (24.5–62.3) 80.5 (p < 0.0001) 0.2144 93.8% (89.1–96.5%) 0–98.3
Other populations at high risk 4 283 13.0–63.0 57.5 (36.8–76.9) 34.6 (p < 0.0001) 0.0393 91.3% (80.9–96.1%) 0.0–100
Populations at intermediate risk
Healthcare workers 10 3,402 0.0–42.1 8.4 (3.7–14.8) 274.4 (p < 0.0001) 0.0891 96.7% (95.4–97.7%) 0–37.9
Diabetic patients 6 1,384 12–60.3 24.7 (6.0–50.4) 415.1 (p < 0.0001) 0.4330 98.8% (98.3–99.1%) 0–100
Household contacts of HCV infected 
persons 13 2,339 0–46.0 13.7 (7.6–21.1) 260.2 (p < 0.0001) 0.1197 95.4% (93.6–96.7%) 0–49.3
Hospitalized patients 6 401 0–90.0 15.9 (0–57.8) 411.1 (p < 0.0001) 1.221 98.8% (98.3–99.1%) 0–100
Other populations at intermediate risk 10 1,547 8.4–41.4 15.2 (11.3–19.4) 39.5 (p < 0.0001) 0.0234 77.2% (58.1–87.6%) 4.2–31.0
Populations with liver-related conditions
Hepatocellular carcinoma patients 22 5,553 30.0–95.2 74.0 (67.1–80.3) 506.2 (p < 0.0001) 0.1071 95.9% (94.7–96.8%) 39.4–97.2
Liver disease patients 28 34,727 16.4–100 65.6 (60.9–70.2) 1121.2 (p < 0.0001) 0.0582 97.6% (97.1–98.0%) 40.3–87.0
Liver cirrhosis patients 2 130 56.0–75.4 66.0 (45.9–83.6) 5.50 (p = 0.0190) 0.0172 81.8% (23.1–95.7%) 0.0–100
Viral hepatitis patients 14 5,992 4.3–78.7 18.1 (11.4–25.8) 360.8 (p < 0.0001) 0.1152 96.4% (95.1–97.3%) 0–54.2
Non-Hodgkin’s lymphoma patients 6 812 7.4–50.6 35.3 (17.5–55.4) 149.6 (p < 0.0001) 0.2378 96.7% (94.7–97.9%) 0–96.8
Special clinical populations
Special clinical populations 34 5,542 0.5–96.1 35.0 (27.3–43.1) 1,206 (p < 0.0001) 0.2256 97.3% (96.8–97.7%) 1.5–81.8
Table 3. Pooled mean estimates for hepatitis C virus (HCV) antibody prevalence stratified by populations’ 
and subpopulations’ risk of exposure to HCV infection in Egypt. *Q: the Cochran’s Q statistic, a measure 
assessing the existence of heterogeneity in effect size. **τ2: the estimated between-study variance in the double 
arcsine transformed proportions of the true effect sizes. The back-transformed τ2 was not calculated as the 
methodology to do so is not currently available. ǂI²: a measure assessing the magnitude of between-study 
variation that is due to differences in effect size across studies rather than chance. ∥Prediction interval: estimates 
the 95% interval in which the true effect size in a new HCV study will lie. **Abbreviation: CI, confidence 
interval.
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Overview of anti-HCV prevalence. Of the 259 anti-HCV prevalence studies, 117 were among the general 
population (Supplementary Table S2), 35 among populations at high risk (Supplementary Table S3), 32 among 
populations at intermediate risk (Supplementary Table S4), 45 among populations with liver-related conditions 
(Supplementary Table S4), 27 among special clinical populations (Supplementary Table S4), and 3 among mixed 
populations (Supplementary Table S4).
Among the general population (Supplementary Table S2), anti-HCV prevalence varied from 0–51% 
with a median of 13.0%. High prevalence levels were reported among subpopulations including blood 
donors (range = 1.6–34%; median = 9.2%), participants in household-based surveys and village residents 
(range = 0–51%; median = 14.3%), children (range = 0–38%; median = 5.8%), pregnant women and ANC attend-
ees (range = 3.9–19%; median = 10.8%), study controls (range = 0–49.3%; median = 30.2%), and other general 
population groups (range = 0–50%; median = 18.9%).
Among populations at high risk (Supplementary Table S3), anti-HCV prevalence was high ranging from 8.9–
98% with a median of 51.7%. High prevalence levels were reported among subpopulations such as hemodialysis 
patients (range = 27.1–98%; median = 67.5%), multi-transfused patients (range = 17.6–54.9%; median = 38.2%), 
and thalassemia patients (range = 8.9–82%; median = 50.0%). A single study among hemophilic children 
reported anti-HCV prevalence at 40.0%63. The only study among PWID assessed anti-HCV prevalence at 63%64.
Among populations at intermediate risk (Supplementary Table S4), anti-HCV prevalence varied from 
0–90% with a median of 12.6%. The prevalence also varied among subpopulations including healthcare workers 
(range = 0–16.6%; median = 7.5%), household contacts of index patients (range = 0–35.5%; median = 13.7%), 
and diabetic patients (range = 3.6–60.3%; median = 18.0%). Anti-HCV prevalence was further measured at 
15.8%65 and 31.4%66 among prisoners, at 8.4%67 and 10%68 among patients with sexually transmitted infections 
(STIs), at 0%69,70 and 90%71 among hospitalized patients, and at 12.5%72 among barbers and their clients.
Among populations with liver-related conditions (Supplementary Table S4), studies reported anti-HCV prev-
alence in the range of 4.3–100% with a median of 58.2%. Anti-HCV prevalence was measured among acute 
viral hepatitis patients (range = 4.3–29%; median = 12.0%), chronic liver disease patients (range = 38.6–100%; 
median = 69.2%), and hepatocellular carcinoma patients (range = 30–95.2%; median = 76.0%). Among special 
clinical populations (Supplementary Table S4), anti-HCV prevalence ranged from 6.7–96.1% with a median of 
38.0%.
Quality appraisal for HCV antibody incidence and prevalence studies. Summary findings of our 
quality appraisal for HCV antibody incidence and prevalence studies can be found in Supplementary Table S5. 
Details of the quality appraisal for each individual study are included in Supplementary Tables S6–S9.
Briefly, about half of incidence of HCV infection (44.0%) and the majority of anti-HCV prevalence (76.4%) 
studies included at least 100 participants, and hence were considered as having high precision. Almost all inci-
dence of HCV infection and anti-HCV prevalence measures were based on convenience sampling, and hence 
were considered as having high risk of bias (ROB) for this domain. The majority of incidence of HCV infection 
(92.0%) and anti-HCV prevalence (88.0%) studies specified the type of assays used for infection ascertainment. 
The majority of incidence of HCV infection studies (75.0%) with information on infection ascertainment relied 
on recent ELISA tests with higher sensitivity and specificity (3rd generation or more). Meanwhile, only 27.6% of 
anti-HCV prevalence studies with such information reported using 3rd or 4th generation assays. Nearly two thirds 
of studies had missing information on the response rate domain.
Incidence of HCV infection and anti-HCV prevalence studies were overall of acceptable quality. The majority 
of studies (88.0%) were classified as having low ROB in one or more quality domain, and almost half (48.6%) as 
having low ROB in two or more quality domains. High ROB in two or more quality domains was found in only 
6% of studies.
Risk factors for incident HCV infection and factors associated with being infected with HCV 
infection. A total of 53 studies assessed risk factors for incidence of HCV infection or factors associated with 
being infected with HCV infection, using multivariable logistic regression analyses. Commonly reported were 
mass parenteral antischistosomal treatment (PAT) campaign exposure54,66,73–88 and other healthcare exposures 
such as dialysis89–97, transfusion54,57,59,70,77–80,85,86,91,93,95,98–107, surgery47,79,84,101–103,108, frequent injections78,86,103,109, 
and dental procedures65,78,86,88,101,102,108,110. Exposures at the workplace were reported for healthcare workers54,111. 
Studies further linked HCV infection to unsafe practices in the community such as using contaminated needles or 
sharp objects during tattooing65,101, ear piercing65,101, male circumcision by traditional healers101, female circum-
cision (female genital mutilation)112, hijama (cupping)74, or while shaving at community barbers47,79,113. Other 
documented risk factors include inter-familial contacts48,57,89,108 and mother-to-child (vertical) transmission57–62.
Systematic review of HCV genotypes. Figure 2 describes the selection process for HCV genotype stud-
ies following PRISMA guidelines32. Out of the total 5,343 citations identified through screening international and 
regional data sources, 245 reports were considered relevant or potentially relevant after duplicates’ removal and 
titles and abstracts’ screening. Following full-text screening, 43 reports qualified for inclusion in the systematic 
review yielding a total of 47 genotype studies on 4,783 HCV RNA positive individuals.
A single HCV strain was isolated from the vast majority of infected individuals; only 3.2% were infected with 
multiple genotypes (Fig. 3A). Individuals were predominantly infected with genotype 4 regardless of population 
type. Genotype 4 was found among blood donors114–117, pregnant women118, village residents76, outpatients119, 
Egyptian expatriate general populations75,120, thalassemia patients121, hemodialysis patients122, healthcare work-
ers123,124, children of HCV infected mothers60, household contacts of HCV infected individuals52, hospitalized 
populations125, diabetic patients126, hepatocellular carcinoma patients127, chronic liver disease patients83,125,128,129, 
www.nature.com/scientificreports/
9SCIENtIFIC REPoRtS |  (2018) 8:1661  | DOI:10.1038/s41598-017-17936-4
acute viral hepatitis patients130–132, special clinical populations133–139, and mixed populations140–142. Studies also 
identified a wide array of subtypes for genotype 4 (Fig. 3B), with subtype 4a being the most frequently reported 
(12.1%).
HCV genotype distribution (Table 2) indicated the following frequency order: genotype 4 (94.1%), genotype 
1 (4.0%), genotype 2 (1.3%), genotype 3 (0.8%), and genotype 5 (0.1%). A single study reported a case of chronic 
active hepatitis with genotype 10a133—a rare finding37 that was excluded from further analyses. Genotype diver-
sity was low with a relative Shannon Diversity Index of only 14.4% (score: 0.27 out of a maximum of 1.95).
Estimates for the pooled mean anti-HCV prevalence among populations and subpopula-
tions. Results of our meta-analyses for anti-HCV prevalence (Table 3), based on pooling available meas-
ures, indicated a mean prevalence of 11.9% (95% CI = 11.1–12.6%) among general populations, 55.6% (95% 
CI = 49.4–61.7%) among populations at high risk, 14.3% (95% CI = 10.3–18.8%) among populations at inter-
mediate risk, 56.0% (95% CI = 50.4–61.6%) among populations with liver-related conditions, and 35.0% (95% 
CI = 27.3–43.1%) among special clinical populations.
Figure 4. Meta-analysis forest plot for hepatitis C virus (HCV) viremic rate in Egypt. HCV viremic rate is the 
proportion of individuals chronically infected with HCV (HCV RNA positive) among those antibody positive 
for HCV.
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Pooled mean anti-HCV prevalence was estimated for subpopulations of the general population at 10.4% (95% 
CI = 9.6–11.2%) among all blood donors, 7.1% (95% CI = 5.9–8.3%) among family replacement donors, 5.4% 
(95% CI = 4.4–6.5%) among voluntary blood donors, 9.0% (95% CI = 6.0–12.6%) among pregnant women, 6.4% 
(95% CI = 2.9–11.1%) among children, 14.4% (95% CI = 9.3–20.4%) among Egyptian expatriate workers under-
going mandatory pre-employment screening and Egyptians living abroad, and 14.3% (95% CI = 12.3–16.4%) 
among other general populations.
Anti-HCV prevalence was high across subpopulations at high risk with a pooled mean of 65.5% (95% 
CI = 56.5–74.1%) among hemodialysis patients, 46.3% (95% CI = 34.9–57.9%) among thalassemia patients, 
42.9% (95% CI = 24.5–62.3%) among multi-transfused patients, and 57.5% (95% CI = 36.8–76.9%) among other 
high-risk subpopulations.
Pooled mean anti-HCV prevalence among subpopulations at intermediate risk was estimated at 8.4% (95% 
CI = 3.7–14.8%) among healthcare workers, 24.7% (95% CI = 6.0–50.4%) among diabetic patients, 13.7% (95% 
CI = 7.6–21.1%) among household contacts of HCV infected individuals, 15.9% (95% CI = 0–57.8%) among hos-
pitalized patients, and 15.2% (95% CI = 11.3–19.4%) among the remaining intermediate-risk subpopulations.
Pooled mean anti-HCV prevalence among subpopulations with liver-related conditions was estimated at 
74.0% (95% CI = 67.1–80.3%) among hepatocellular carcinoma patients, 65.6% (95% CI = 60.9–70.2%) among 
liver disease patients, 66.0% (95% CI = 45.9–83.6%) among liver cirrhosis patients, 18.1% (95% CI = 11.4–25.8%) 
among viral hepatitis patients, and 35.3% (95% CI = 17.5–55.4%) among non-Hodgkin’s lymphoma patients 
(included as “liver-related” because of potential link to HCV infection33,34).
Considerable heterogeneity in effect size was observed across all meta-analyses (Cochrane’s Q statistic’s 
p-value < 0.0001), with the effect size (HCV prevalence) prediction intervals generally being wide. Most of the 
variability across studies was due to true differences across studies rather than chance (I2 > 77.2%; Table 3).
Number 
of studies
Univariable analyses Multivariable analysis*
OR (95% CI) p-value** AOR (95% CI) p-value‡
Subpopulation type 
(among the general 
population)
Blood donors 111 1 1
Pregnant women/ANC 
attendees 13 0.86 (0.46–1.63) 0.651 1.11 (0.62–1.96) 0.729
Children 16 0.40 (0.22–0.71) 0.002** 0.47 (0.27–0.79) 0.005‡
Egyptian expatriate 
workers undergoing 
mandatory pre-
employment screening 
and Egyptians living 
abroad
23 1.45 (0.88–2.37) 0.141 0.98 (0.43–2.21) 0.956
Other general 
population groups 99 1.47 (1.09–1.98) 0.012
** 1.63 (1.17–2.28) 0.004‡
Region
Upper Egypt 9 1 1
Middle Egypt 54 1.69 (0.78–3.67) 0.186 1.57 (0.79–3.12) 0.199
Lower Egypt 89 2.42 (1.14–5.14) 0.022** 1.92 (0.98–3.75) 0.057
Canal & Sinai 16 1.65 (0.67–4.06) 0.271 0.62 (0.27–1.40) 0.247
National 24 1.48 (0.64–3.45) 0.357 0.86 (0.36–2.06) 0.735
Mixed regions 39 4.00 (1.80–8.87) 0.001** 1.85 (0.80–4.27) 0.150
Regions outside Egypt 15 2.58 (1.04–6.41) 0.041** 2.41 (0.75–7.71) 0.139
Unspecified 16 3.24 (1.32–7.96) 0.011** 1.62 (0.73–3.63) 0.236
Study site
Blood bank 77 1
National 24 0.68 (0.40–1.14) 0.143 — —
Clinical 72 1.04 (0.72–1.49) 0.844 — —
Others 74 1.08 (0.75–1.56) 0.663 — —
Unspecified 15 1.56 (0.83–2.92) 0.167 — —
Sampling methodology
Probability-based 66 1
Non-probability based 196 0.72 (0.53–0.99) 0.044** 0.70 (0.46–1.05) 0.086
Sample size
<100 63 1
>=100 199 0.73 (0.53–1.00) 0.052** 1.14 (0.85–1.54) 0.385
Publication year 262 0.93 (0.92–0.95) 0.000** 0.94 (0.92–0.96) 0.000‡
Median year of data 
collection 197 1.0 0.458 — —
Table 4. Univariable and multivariable meta-regression models for HCV antibody prevalence among the 
general population in Egypt. *Total between-study variation explained by final multivariable model: 29.0%. 
**Factors with p-value < 0.1 were eligible for inclusion in the multivariable model. ‡Factors with p-value < 0.05 
were considered statistically significant. †Abbreviations: AOR, adjusted odds ratio; OR, odds ratio; CI, 
confidence interval.
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HCV RNA prevalence overview and pooled mean estimate for HCV viremic rate. Our search 
identified 77 HCV RNA measures, of which 53 were among anti-HCV positive individuals (Supplementary 
Tables S2–S4). HCV viremic rate (HCV RNA prevalence among anti-HCV positive individuals) ranged from 
9.1–100% with a median of 66.7%. Meanwhile, HCV RNA prevalence in samples including individuals irrespec-
tive of their antibody status ranged from 0–86.6% with a median of 24.9%.
HCV viremic rate was reported among the general population (range = 26.9–100%; median = 65.3%; 
Supplementary Table S2) and its subpopulations including children (range = 33.3–75.9%; median = 41.0%), 
pregnant women (range = 26.9–79.0%; median = 55.1%), and other general populations (range = 29.7–100%; 
median = 69.5%). Among populations at high risk (Supplementary Table S3), HCV viremic rate was reported 
among thalassemia patients (range = 55–100%; median = 74.3%), and was measured at 100%143 among 
multi-transfused children, and at 47.5%63 among hemophilic children.
HCV viremic rate was reported among patients with liver-related conditions in the range of 55.0–88.7% with 
a median of 69.6% (Supplementary Table S4), such as patients with acute viral hepatitis (87.0%)132, chronic liver 
disease (55.0%83 and 69.6%80), non-Hodgkin’s lymphoma (88.7%)144, and liver complaints (57.7%)139. It was also 
reported in the range of 9.1–100% with a median of 69.4% among populations at intermediate risk, and in the 
range of 38.5–76.8% with a median of 59.6% among special clinical populations (Supplementary Table S4).
Figure 4 shows the forest plot for the meta-analysis of HCV viremic rate in Egypt. The pooled mean viremic 
rate was estimated at 66.7% (95% CI = 61.7–71.5%). Substantial heterogeneity was detected across studies 
(I2 = 94.8%; Cochrane’s Q statistic’s p-value < 0.0001), with an effect size (HCV viremic rate) prediction interval 
ranging from 30.4–94.6%.
Associations with anti-HCV prevalence among the general population and sources of hetero-
geneity across studies. Table 4 shows the results of our meta-regression models assessing the predictors 
of anti-HCV prevalence among the general population. Our univariable meta-regression analyses identified sub-
population type, region, sampling methodology, sample size, and publication year as significant and eligible for 
inclusion in the multivariable meta-regression model. The latter showed that, compared to blood donors, children 
had 53% lower odds for anti-HCV prevalence (adjusted odds ratio (AOR) = 0.47; 95% CI = 0.27–0.79), while 
other general population groups had 63% higher odds (AOR = 1.63; 95% CI = 1.17–2.28). Our results further 
indicated 6% lower odds for anti-HCV prevalence for each one year increment in publication year (AOR = 0.94; 
95% CI = 0.92–0.96). All other examined predictors were not retained in the final multivariable model, though 
Lower Egypt as a region and non-probability sampling as a study sampling methodology were, with borderline 
statistical significance, positively and negatively associated, respectively, with anti-HCV prevalence.
Discussion
We presented a comprehensive characterization of HCV epidemiology in Egypt by, first, updating and expanding 
our earlier systematic review21 of HCV antibody incidence and prevalence. The updated and expanded review 
affirmed high HCV infection levels across all populations (Supplementary Tables S2–S4) with evidence for ongo-
ing transmission (Table 1). We also conducted a systematic review of HCV genotypes that highlighted the limited 
diversity of genotypes in Egypt and the predominance of genotype 4, which alone accounted for 94% of HCV 
infections (Table 2 and Fig. 3). Our meta-analyses for the pooled mean anti-HCV prevalence among populations 
and subpopulations at various risks of exposure quantified prevalence levels across diverse population strata and 
suggested that most HCV exposures are linked to medical care (Table 3). Our meta-analysis for HCV viremic rate 
indicated that 67% of those anti-HCV positive in Egypt are chronically infected and in need of treatment (Fig. 4). 
Lastly, our meta-regression analyses highlighted a declining trend for anti-HCV prevalence in Egypt suggesting a 
rapidly contracting HCV epidemic in this country (Table 4).
One of the key public health questions in Egypt today is whether incidence of HCV infection is ongoing and at 
what level21. Our updated and expanded systematic review identified 25 HCV incidence measures (Table 1), out 
of which only five were identified in our previous review21. Incidence levels of HCV infection were relatively high, 
even among the general population, confirming endemic transmission of HCV in Egypt. High seroconversion 
risks for anti-HCV reaching up to 100% were found among clinical populations, namely hemodialysis patients, 
indicating exposure through medical care. However, some of these incidence studies may have been outdated, 
while others were conducted in specific locations thus potentially limiting their representativeness of current 
HCV incidence in the population at large.
This being said, a main finding of our study is the statistically significant decline in anti-HCV prevalence in the 
general population year by year (Table 4). The decrease in the AOR of 6% per year suggests a rapid decline in inci-
dence of HCV infection, consistent with a contracting HCV epidemic in Egypt. Recent work modeling the Egypt 
epidemic also supports this finding5. Here, HCV incidence rate was estimated at 110 per 100,000 person-years in 
2015, and was projected to decline by 33% over the next decade (even assuming no interventions) to reach 74 per 
100,000 person-years in 20305. These findings suggest that the improvements in blood screening and infection 
control over the last two decades have made an impact on reducing HCV transmission in Egypt. In a context of 
a rapidly scaled-up DAA treatment program18, and its impact as treatment for prevention5, Egypt will likely pro-
gress robustly towards HCV elimination by 2030, after enduring an epidemic of historic proportion.
Another key public health question in Egypt today is determining anti-HCV prevalence among different 
populations and identifying who should be tested for HCV in Egypt. A total of 259 anti-HCV prevalence meas-
ures were identified in the present review (Supplementary Tables S2-S4), compared to only 103 in our earlier 
review21. Despite the sizable addition, findings of both reviews, as well as the meta-analyses (Table 3), converged 
to the same conclusion of a generalized HCV epidemic in Egypt. HCV prevalence levels were considerably higher 
than global levels2,3,13,145 across all population groups, even those conventionally at low risk of exposure such as 
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pregnant women (Table 3). High mean anti-HCV prevalence was also found among children confirming recent 
ongoing transmission (Table 3). Pooled estimates for mean anti-HCV prevalence among the different clinical 
populations were substantial, with about half of these populations being HCV antibody positive (Table 3).
These findings suggest that clinical populations should be prioritized for HCV screening and treatment. 
Screening programs targeting other populations such as healthcare workers, household contacts of HCV infected 
patients, and populations at lower risk such as blood donors, pregnant women, and children, may not be as 
cost-effective and should have lower priority for the time being. As resources are freed and available, screening 
programs for these populations should be gradually considered.
Our review identified risk factors for incidence of HCV infection and factors associated with being infected 
with HCV infection. These factors supported healthcare exposures as drivers of HCV transmission such as 
dialysis89–97, blood transfusion54,57,59,70,77–80,85,86,91,93,95,98–107, surgery47,79,84,101–103,108, and even minor procedures 
such as dental work65,78,86,88,101,102,108,110. Our review further suggested a role for community-related expo-
sures47,65,74,79,101,112,113 including informal healthcare practices such as male circumcision by traditional healers101, 
female circumcision112, and hijama (cupping)74. Mother-to-child transmission has been also documented57–62—a 
finding in line with a recent estimate of 3,000-5,000 HCV infections per year through vertical transmission in 
Egypt146.
Among other key public health issues in Egypt today is the contribution of HCV infection to liver disease. Our 
results show that two thirds of patients with liver-related conditions are infected with HCV (Table 3). The high 
pooled estimates for the mean anti-HCV prevalence among different populations with liver-related conditions 
such as hepatocellular carcinoma, liver cirrhosis, and liver disease patients (Table 3) support the prominent role 
that HCV plays in liver disease incidence in Egypt.
Our pooled estimate of 12% for the mean anti-HCV prevalence among the general population (Table 3) is in 
line with EDHS findings of a national prevalence of 14.7%11 in 2008 and 10.0%12 in 2015. Of notice, however, that 
these EDHS estimates include only the adult population aged 15–59 years of age and our pooled estimate encom-
pass all HCV prevalence data from all years and ages—including those older than 60 years of age. The latter age 
group is the most affected by the HCV epidemic in Egypt21,147–149.
The diversity of HCV genotypes was limited compared to international levels37,145,150, quantified at only 14.4% 
(Table 2) using Shannon’s Diversity Index36. Genotype 4 was by far the most dominant accounting for >90% of 
infections, with limited presence of other genotypes (Fig. 3A and Table 2). Some diversity was observed across 
subtypes of genotype 4, with subtype 4a being the most frequently reported (Fig. 3B). These findings are consist-
ent with recent global reviews of HCV genotypes that reported on Egypt37,145,150, but our findings are based on 
a much larger sample size pooled through 47 studies. The rather limited diversity in HCV genotypes in Egypt 
contrasts with what is seen in other MENA countries, including neighboring ones, such as in the Fertile Crescent 
and Iran where diversity ranged from as low as 35% in Jordan to as high as 66% in Lebanon29,30.
The dominance of genotype 4 affirms the special nature of the Egyptian epidemic and its link to a cohort 
effect148,149 and specific events, such as PAT campaigns and more generally healthcare practices before the discov-
ery of the virus20,149,151,152. The presence however of other genotypes, and some diversity in genotype 4 subtypes, 
may suggest the existence of different transmission networks in Egypt that need to be elucidated.
HCV viremic rate can inform HCV estimates and likelihood of identifying chronic infection in different 
populations. Importantly, it can also play an important role over the next 13 years in monitoring scale-up of HCV 
treatment coverage and progress towards HCV elimination by 2030. Our findings showed that 67% of anti-HCV 
positive Egyptians are chronically infected (Fig. 4). This estimate is lower than what is found in the USA, where 
the viremic rate was estimated at 74% (Chemaitelly, unpublished work) by pooling several rounds of the National 
Health and Nutrition Examination Survey (NHANES), a nationally representative population-based survey153. 
It is not likely that this difference in viremic rate is explained by differential treatment coverage, since mass HCV 
treatment has been launched very recently5. It is possible, however, that this difference may reflect differential 
modes of exposure—HCV transmission in the USA is driven largely by injecting drug use2,3,13, while the epidemic 
in Egypt is generalized and is driven mainly by medical care. Other possible explanations include differences in 
HCV spontaneous clearance rates resulting from differences in HCV circulating genotypes154, other host and 
virus factors155–159, and female sex154,160,161. The latter is likely to be under-represented in epidemics driven pri-
marily by injecting drug use162.
Our study is limited by the quantity and quality of available evidence for specific populations. In particular, 
only one study was identified for PWID64. With a PWID population proportion of 0.16% in Egypt22,162,163, inject-
ing drug use could be an important driver of current HCV incidence. Its relative contribution is likely also to 
grow as the generalized epidemic contracts further over the coming years and becomes a concentrated epidemic 
in specific populations. Increasing evidence supports a growing role for injecting drug use as a driver of new HCV 
infections in Egypt164,165.
For some of the incidence studies, only seroconversion risk for anti-HCV was reported. Such studies, espe-
cially the older ones, may have used less sensitive assays to assess HCV exposure. This may bias the estimated 
risk of seroconversion in these studies—in such high HCV prevalence settings false negatives may have been 
identified erroneously as seroconverters.
In conclusion, Egypt is challenged with a high anti-HCV prevalence in virtually all population groups and 
strata, with evidence for some ongoing HCV transmission. Medical care seems to be the primary source of past 
and present HCV transmission, with about half of individuals belonging to the clinical populations at high risk 
being infected. Genotype diversity is low with Genotype 4 being (by far) the dominant genotype. Two thirds of 
anti-HCV positive Egyptians are chronically infected and in need of treatment. Despite the large scale epidemic in 
Egypt, HCV antibody incidence and prevalence appear to be declining rapidly consistent with a contracting epi-
demic. With the recent progress in scaling up Egypt’s DAA treatment program, Egypt is likely to make ambitious 
strides towards HCV elimination by 2030 after enduring an epidemic of historic proportion.
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